Flax Pond Capital LLC Makes New Investment in Structure Therapeutics Inc. Sponsored ADR $GPCR

Flax Pond Capital LLC bought a new stake in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) in the 4th quarter, Holdings Channel reports. The firm bought 48,721 shares of the company’s stock, valued at approximately $3,389,000. Structure Therapeutics accounts for about 2.5% of Flax Pond Capital LLC’s portfolio, making the stock its 19th largest holding.

Other large investors have also recently made changes to their positions in the company. Geode Capital Management LLC grew its stake in shares of Structure Therapeutics by 18.5% in the 2nd quarter. Geode Capital Management LLC now owns 54,181 shares of the company’s stock worth $1,124,000 after buying an additional 8,444 shares during the last quarter. Invesco Ltd. raised its stake in Structure Therapeutics by 7.6% during the second quarter. Invesco Ltd. now owns 424,548 shares of the company’s stock valued at $8,805,000 after buying an additional 30,162 shares during the last quarter. Marshall Wace LLP boosted its holdings in Structure Therapeutics by 474.9% in the second quarter. Marshall Wace LLP now owns 176,060 shares of the company’s stock worth $3,651,000 after acquiring an additional 145,434 shares in the last quarter. Jump Financial LLC boosted its holdings in Structure Therapeutics by 105.9% in the second quarter. Jump Financial LLC now owns 63,234 shares of the company’s stock worth $1,311,000 after acquiring an additional 32,524 shares in the last quarter. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of Structure Therapeutics in the second quarter worth $3,480,000. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Structure Therapeutics Stock Performance

Shares of GPCR opened at $44.51 on Friday. The company has a market cap of $3.16 billion, a price-to-earnings ratio of -51.16 and a beta of -1.35. The business’s fifty day simple moving average is $42.71 and its two-hundred day simple moving average is $57.50. Structure Therapeutics Inc. Sponsored ADR has a 12 month low of $15.80 and a 12 month high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.04. As a group, research analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on GPCR shares. Leerink Partners restated an “outperform” rating on shares of Structure Therapeutics in a report on Monday, March 16th. HC Wainwright dropped their price target on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a research note on Thursday, June 11th. Canaccord Genuity Group began coverage on shares of Structure Therapeutics in a research report on Monday, April 27th. They set a “buy” rating and a $101.00 price objective on the stock. BMO Capital Markets set a $145.00 price objective on shares of Structure Therapeutics and gave the company an “outperform” rating in a research note on Tuesday, March 17th. Finally, Wall Street Zen cut shares of Structure Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Three analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $106.75.

Structure Therapeutics Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.